Avery Stuart

Dr. Avery Stuart


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2026 in Medicina
Verified
Journal Article
Open access
PDF file
ASAlyssa Mariah Sanchez
Alyssa Mariah Sanchez
MHMehde Hasan
Mehde Hasan
KPKhalil Pathan
Khalil Pathan
ASAvery Stuart
Avery Stuart
PPPurvi Parwani
Purvi Parwani
Tricuspid regurgitation (TR) is a heterogeneous valvular disorder affecting an estimated 1.6 million adults in the United States, with increasing clinical relevance in the era of transcatheter intervention. Accurate etiologic classification is essential because primary, secondary, and cardiac implantable electronic device (CIED)-related TR arise through distinct mechanisms and carry different imaging, prognostic, and therapeutic implications. Contemporary multimodality imaging, including transthoracic echocardiography (TTE), three-dimensional echocardiography, transesophageal echocardiography (TEE), cardiac magnetic resonance (CMR), and cardiac computed tomography (CT), enables integrated assessment of valve anatomy, right-heart remodeling, pulmonary hemodynamics, and procedural suitability. In this narrative review, we propose a phenotype-based approach to secondary TR organized across six domains: chamber morphology, right atrial mechanics, annular geometry, leaflet morphology, right ventricular systolic function, and pulmonary hemodynamics. Integration of these domains may support assessment of atrial secondary TR (A-STR) and ventricular secondary TR (V-STR), while recognizing patients with overlapping atrial and ventricular features. Throughout, we distinguish consensus-derived phenotyping parameters from supportive prognostic associations and identify areas where evidence remains insufficient. We further discuss how multimodality imaging may inform procedural planning and intervention timing and highlight emerging echocardiographic markers, including right atrial reservoir strain, effective right ventricular ejection fraction (eRVEF), and CMR tissue characterization that warrant prospective validation for phenotyping, risk stratification, and assessment of myocardial reversibility. Together, this conceptual framework, which requires prospective validation, is intended to complement severity-based classification with a mechanism-informed approach to TR diagnosis and management.

31 July 2026 in Hematology Reports
Verified
Journal Article
Open access
PDF file
KLKareem Latif
Kareem Latif
ICIsaiah Courtad
Isaiah Courtad
ASAvery Stuart
Avery Stuart
FAFaisal Ansari
Faisal Ansari
RSRavand Samaeekia
Ravand Samaeekia
MAMojtaba Akhtari
Mojtaba Akhtari
Background: Interim PET after two cycles (PET2) has historically guided risk-adapted therapy in Hodgkin lymphoma (HL). Its value with frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV + AVD) is uncertain, as BV + AVD improves progression-free survival and may reduce the prognostic relevance of early metabolic response. Our aim was to assess whether PET2 retains prognostic utility in HL patients treated with BV + AVD. Methods: We retrospectively reviewed 55 newly diagnosed classical HL patients treated with frontline BV + AVD. The primary endpoint was PET2 performance for predicting EOT PET positivity. Sensitivity, specificity, predictive values, and likelihood ratios were calculated with 95% confidence intervals. Results: Median age was 22 years (range 11–77), 49% were male, and 73% had stage III–IV disease. PET2 was negative in 51 patients (92.7%) and positive in 4 (7.3%). EOT PET was negative in 48 (87.3%) and positive in 7 (12.7%). Of seven EOT PET-positive patients, three were PET2-positive and four PET2-negative. Of 48 EOT PET-negative patients, 47 were PET2-negative and 1 PET2-positive. PET2 sensitivity was 42.9%, specificity 97.9%, positive predictive value 75.0%, and negative predictive value 92.2%. Positive likelihood ratio was 20.6; negative likelihood ratio was 0.58. Conclusions: In HL patients treated with BV + AVD, most achieve PET2 negativity, limiting interim PET discrimination. Negative PET2 adds little reassurance beyond the high baseline success rate, while positive PET2 is uncommon and identifies only a subset of eventual treatment failures. These findings question the routine use of PET2 to guide therapy in the BV + AVD era.